Marion Wiesmann

Biochemistry, Genetics and Molecular Biology · Life Sciences

23h-index5.4kcitations94works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

PI3K/AKT/mTOR signaling in cancer(31), Chronic Lymphocytic Leukemia Research(30), Cancer-related Molecular Pathways(29), Advanced Breast Cancer Therapies(13), Oral and gingival health research(12)

Publications94 total

Data from Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
2023Open Access
Supplementary Figure 1 from Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
2023Open Access
Supplementary Figure 4 from Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
2023Open Access
Data from Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
2023Open Access
Supplementary Materials, Tables 1-2, Figure Legends 1-8 from Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
2023Open Access
Supplementary Table II from Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097
2023Open Access
Supplementary Figure 2 from Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
2023Open Access
Supplementary Figure 8 from Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
2023Open Access
Supplementary Figure 6 from Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
2023Open Access
Supplementary Figure 1 from Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
2023Open Access
Supplementary Figure 8 from Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
2023Open Access
Supplementary Figure 2 from Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
2023Open Access
Supplementary Figure 5 from Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
2023Open Access
Supplementary Figure 3 from Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
2023Open Access
Supplementary Figures 1-7 from Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097
2023Open Access
Supplementary Figures 1-7 from Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097
2023Open Access
Supplementary Materials, Tables 1-2, Figure Legends 1-8 from Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
2023Open Access
Supplementary Table I from Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097
2023Open Access
Supplementary Figure 2 from Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
2023Open Access
Supplementary Figure 7 from Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
2023Open Access
page 1 of 5Next →

Frequent Co-authors

William R. Sellers(21), Francesco Hofmann(20), Sébastien Jeay(16), Stéphane Ferretti(15), Daniel Guthy(15), Christian Schnell(14), Sabina Pecchi(13), Dario Sterker(13), Ensar Halilovic(13), Alan Huang(11), Saskia M. Brachmann(11), Christine Fritsch(11), Robert Schlegel(11), Charles F. Voliva(11), Sauveur-Michel Maira(10), Patrick Chêne(10), Pascal Furet(10), Markus Wartmann(10), Audrey Kauffmann(9), Alain De Pover(9)